Answers are grounded in this paper and cite their sources.
Novartis is set to buy the German drugmaker MorphoSys for $3.0 billion. MorphoSys has two wholly owned programs. One is pelabresib, which is designed to block bromodomain and extraterminal domain (BET) proteins as a treatment for myelofibrosis and essential thrombocythemia. Pelabresib is up for review by the US Food and Drug Administration this year. The other is tulmimetostat, which targets the genes EZH1 and EZH2 to treat multiple types of cancer.
No takes yet. Share an insight, caveat, or question.
Rowan Walrath (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: